Abstract: This invention relates to DNA libraries, in particular a human VNO cDNA library is described. Pheromone receptor cDNA once isolated is transfected into competent cells. The transfected cell lines provide a scaleable source of homogeneous material to develop efficient, automated high throughput screening assays for new vomeropherins, and thereby reduce the ongoing need for human volunteers in the preclinical phases of drug discovery. Identification and characterization of the human VNO receptor(s) will facilitate the development and commercialization of vomeropherins with improved specificity, and enhanced therapeutic efficacy in the treatment of the target diseases.

Abstract: This invention relates to a human pheromone receptor. Specifically, a human VNO receptor and its mRNA, cDNA and amino acid sequence are disclosed. Expression vectors comprising a nucleotide sequence encoding a human pheromone receptor are contemplated. Cells may be transformed with said expression vectors. Cells expressing the pheromone receptor in vitro may be utilized to screen drug candidates to identify agonists and/or antagonists of receptor activation. Drugs so identified find a therapeutic use in psychiatric disorders and neuroendocrine disorders and diseases.

Abstract: This invention relates to DNA libraries, in particular a human VNO cDNA library is described. Pheromone receptor cDNA once isolated is transfected into competent cells. The transfected cell lines provide a scaleable source of homogeneous material to develop efficient, automated high throughput screening assays for new vomeropherins, and thereby reduce the ongoing need for human volunteers in the preclinical phases of drug discovery. Identification and characterization of the human VNO receptor(s) will facilitate the development and commercialization of vomeropherins with improved specificity, and enhanced therapeutic efficacy in the treatment of the target diseases.

Abstract: The present invention relates to mammalian receptors, particularly novel pheromone receptors and the expression of these receptors in selected cells and tissues. More specifically, the invention encompasses a novel human pheromone receptor. The invention contemplates nucleic acid molecules and fragment(s) thereof encoding a human pheromone receptor, and agents that specifically bind to the polypeptides comprising the human pheromone receptor. The invention also encompasses vectors and cells for producing the nucleic acid molecules encoding the human pheromone receptor as well as vectors and cells for expressing receptor polypeptides. The invention further relates to methods for isolation, characterization and detection of the nucleic acid molecules, polypeptides, and agents that bind to the receptor. The invention also encompasses diagnosis and treatment of diseases or disorders related to the aberrant expression of the human pheromone receptor.

Abstract: This invention relates to DNA libraries, in particular a human VNO cDNA library is described. Pheromone receptor cDNA once isolated is transfected into competent cells. The transfected cell lines provide a scaleable source of homogeneous material to develop efficient, automated high throughput screening assays for new vomeropherins, and thereby reduce the ongoing need for human volunteers in the preclinical phases of drug discovery. Identification and characterization of the human VNO receptor(s) will facilitate the development and commercialization of vomeropherins with improved specificity, and enhanced therapeutic efficacy in the treatment of the target diseases.

Abstract: This invention relates to a human pheromone receptor. Specifically, a human VNO receptor and its mRNA, cDNA and amino acid sequence are disclosed. Expression vectors comprising a nucleotide sequence encoding a human pheromone receptor are contemplated. Cells may be transformed with said expression vectors. Cells expressing the pheromone receptor in vitro may be utilized to screen drug candidates to identify agonists and/or antagonists of receptor activation. Drugs so identified find a therapeutic use in psychiatric disorders and neuroendocrine disorders and diseases.